The cells aren't matched as they use iPSCs in order to provide a renewable cell source for consistent and repeated manufacture of homogeneous cell products.
The company uses addition genetic engineering to try and reduced (or stop) rejection by the recipient's T and NK cells. They have shown already they can administer up to six treatments without any DLTs.
Market Data 
Markets 
AI
